Related Experiment Video

Updated: Mar 17, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

808

Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma

Thomas S Y Chan1, Pek-Lan Khong1, Yok-Lam Kwong2

  • 1Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong.

Annals of Hematology
|July 31, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Related Experiment Videos

Last Updated: Mar 17, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

808
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

Articles linked to this work by shared authors, journal, and citation graph.

A Strategic Framework to Address Growing Imbalances between Physician Supply and Demand for Radiology: A Review from the International Society for Strategic Studies in Radiology.

Radiology·2026

High-throughput bead-based cytokine profiling reveals dynamic immune signatures and identifies candidate exploratory biomarkers in CAR-T therapy.

Chemical science·2026

Limbic free-water alterations as neuroimaging biomarkers for predicting phenoconversion in prodromal Parkinson's disease.

Parkinsonism & related disorders·2026

Clinical Translation of a Dual Integrin-and GRPR-targeting PET Radiotracer 68 Ga-DOTA-RGD-RM26 in Glioma.

Clinical nuclear medicine·2025

Glymphatic Function in Prodromal Parkinson's Disease: Associations With Symptoms, Gray Matter Volume, and Phenoconversion Risk.

European journal of neurology·2025

Epigenetics in Heart Failure.

International journal of molecular sciences·2024

Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia.

Annals of hematology·2026

Change in COVID-19 outcomes in lymphoma patients across pandemic waves: results of the COVID-19-lymphoma registry of the Bavarian Cancer Research Center (BZKF) 2020-2022.

Annals of hematology·2026

Diagnosis and treatment of familial hemophagocytic lymphohistiocytosis with isolated central nervous system involvement: A case report.

Annals of hematology·2026

Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.

Annals of hematology·2026

Deep learning differentiates myeloproliferative neoplasms and predicts JAK2 and CALR mutations from bone marrow smears.

Annals of hematology·2026

Liver iron concentration and renal dysfunction in β-thalassemia: a case series and exploratory clinical observations.

Annals of hematology·2026

Reversing Dysfunction of CCR9+ Regulatory T Cells by Targeting the IL-21/IL-17 Axis Improves Type 1 Diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026

The Patient With Multiple Alloantibodies: A Systematic Strategy for Antibody Identification and Transfusion Management.

Case reports in immunology·2026

Efficacy and safety of bispecific antibodies versus other antitumor therapies in solid tumors: a systematic review and meta-analysis.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us